An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

July 2, 2024

Study Completion Date

August 27, 2024

Conditions
Resistant Hypertension
Interventions
BIOLOGICAL

XXB750 drug

SC injection

OTHER

Placebo

SC injection

Trial Locations (78)

110

Novartis Investigative Site, Taipei

1190

Novartis Investigative Site, Vienna

1202

Novartis Investigative Site, Sofia

1233

Novartis Investigative Site, Sofia

1709

Novartis Investigative Site, Sofia

5000

Novartis Investigative Site, Adelaide

5800

Novartis Investigative Site, Pleven

6000

Novartis Investigative Site, Perth

8036

Novartis Investigative Site, Graz

10002

Novartis Investigative Site, Taipei

10787

Novartis Investigative Site, Berlin

11217

Novartis Investigative Site, Taipei

12808

Novartis Investigative Site, Prague

20110

Manassas Clinical Research Center, Manassas

20122

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

20706

Capitol Cardiology Associates, Lanham

20744

Anderson Medical Research, Ft. Washington

20745

MD Medical Research, Oxon Hill

23219

Dominion Medical Associates, Richmond

25123

Novartis Investigative Site, Brescia

28041

Novartis Investigative Site, Madrid

29607

The Research Center of the Upstate, Greenville

30101

American Clinical Trials, Acworth

31008

Novartis Investigative Site, Pamplona

32216

Jacksonville Center for Clinical Research, Jacksonville

33014

Inpatient Research Clinical LLC, Miami Lakes

33305

Novartis Investigative Site, Taoyuan District

33449

Cardiology Partners Clinical Research Institute, Wellington

33467

Canvas Clinical Research, Lake Worth

35206

Parkway Medical Center, Birmingham

36207

Pinnacle Research Group Llc, Anniston

37044

Novartis Investigative Site, Tours

37388

Tennessee Center For Clinical Trials, Tullahoma

40138

Novartis Investigative Site, Bologna

41014

Novartis Investigative Site, Seville

45801

NexGen Research, Lima

46010

Novartis Investigative Site, Valencia

56124

Novartis Investigative Site, Pisa

59000

Novartis Investigative Site, Lille

60594

Novartis Investigative Site, Frankfurt am Main

67207

Alliance for Multispecialty Resrch, Wichita

75015

Novartis Investigative Site, Paris

89077

Novartis Investigative Site, Ulm

91054

Novartis Investigative Site, Erlangen

92780

Orange County Research Center, Tustin

93009

Novartis Investigative Site, Bobigny

101200

Novartis Investigative Site, Beijing

200025

Novartis Investigative Site, Shanghai

266000

Novartis Investigative Site, Qingdao

510080

Novartis Investigative Site, Guangzhou

95821-2134

Clinical Trials Research Sacramento, Sacramento

014010

Novartis Investigative Site, Baotou

250 01

Novartis Investigative Site, Brandýs nad Labem

04910

Novartis Investigative Site, Elsterwerda

818-8516

Novartis Investigative Site, Chikushino-shi

920 8650

Novartis Investigative Site, Kanazawa

232 0024

Novartis Investigative Site, Yokohama

239-8567

Novartis Investigative Site, Yokosuka

596-0042

Novartis Investigative Site, Kishiwada

103-0027

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Chuo-ku

104-0031

Novartis Investigative Site, Chuo Ku

1105 AZ

Novartis Investigative Site, Amsterdam

81-157

Novartis Investigative Site, Gdynia

40-648

Novartis Investigative Site, Katowice

30-002

Novartis Investigative Site, Krakow

52-416

Novartis Investigative Site, Wroclaw

085 01

Novartis Investigative Site, Bardejov

040 01

Novartis Investigative Site, Košice

949 01

Novartis Investigative Site, Nitra

089 01

Novartis Investigative Site, Svidník

08035

Novartis Investigative Site, Barcelona

08221

Novartis Investigative Site, Terrassa

08025

Novartis Investigative Site, Barcelona

EC1M 6BQ

Novartis Investigative Site, London

W1T 7HA

Novartis Investigative Site, London

M6 8HD

Novartis Investigative Site, Salford

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY